Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 May 2022

Tsai Ming-Shao, Shih Wei-Tai, Yang Yao-Hsu, Lin Yu-Shih, Chang Geng-He, Hsu Cheng-Ming, Yeh Reming-Albert, Shu Li-Hsin, Cheng Yu-Ching, Liu Hung-Te, Wu Yu-Huei, Wu Yu-Heng, Shen Rou-Chen, Wu Ching-Yuan

Abstract excerpt

At the time of writing, more than 440 million confirmed coronavirus disease 2019 (COVID-19) cases and more than 5.97 million COVID-19 deaths worldwide have been reported by the World Health Organization since the start of the outbreak of the pandemic in Wuhan, China. During the COVID-19 pandemic, many variants of SARS-CoV-2 have arisen because of high mutation rates. N501Y, E484K, K417N, K417T, L452R and T478K in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pandemics

Share to Protein Binding

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 35279013
DOI: 10.1016/j.biopha.2022.112802
PMCID: PMC8906167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.PMID 35279013Read ↗

GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.Semantic proximity Read ↗

The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and AntibodiesSemantic proximity Read ↗

Inhibition of ACE2‐Spike Interaction by an ACE2 Binder Suppresses SARS‐CoV‐2 EntrySemantic proximity Read ↗

Coronil biochemically inhibits the interaction of various clinically relevant mutants of SARS-CoV-2 Spike Proteins (Omicron Variants) with human ACE2 receptorSemantic proximity Read ↗

Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interactionSemantic proximity Read ↗

Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interactionSemantic proximity Read ↗

Phylogenetic analysis and In silico Screening of drug targets for ACE2 in Human and Spike Glycoprotein in Sars-CoV-2 for control of COVID19Semantic proximity Read ↗

A new proposed mechanism of some known drugs targeting the SARS-CoV-2 spike glycoprotein using molecular dockingSemantic proximity Read ↗

Epigallocatechin Gallate from Green Tea Effectively Blocks Infection of SARS-CoV-2 and New Variants by Inhibiting Spike Binding to ACE2 ReceptorSemantic proximity Read ↗

COVID-19, Infection Inhibitors and MedicinesSemantic proximity Read ↗

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19Semantic proximity Read ↗

Structural Insights Into the Design of Peptide-based Drug or Diagnostic Reagent Antagonizing SARS-COV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.